Phage therapy

BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023

Retrieved on: 
Thursday, September 7, 2023
International, Part, ERS, Date, Psoriatic arthritis, Patient, NESS, European Respiratory Society, CEST, Cystic fibrosis, Phage therapy, Trial of the century, Congress, International Congress on Tuberculosis, CF, NYSE, Pharmaceutical industry

CAMBRIDGE, Mass.

Key Points: 
  • CAMBRIDGE, Mass.
  • and NESS ZIONA, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will present data from Part 1 of its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa (PsA) pulmonary infections in patients with cystic fibrosis (“CF”) at European Respiratory Society (ERS) International Congress 2023, which is being held September 9-13, 2023, in Milan, Italy.
  • The abstract was submitted as a Late-Breaking Abstract and selected for oral presentation at the conference.
  • The Phase 1b/2a data for BX004 will also be available as an e-poster on the virtual congress platform.

BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, August 9, 2023
Insurance, Communication, CFA, Cystic fibrosis, Data analysis, Patient, Cystic Fibrosis Foundation, Disease, NYSE, PIPE, Policy, Pharmacokinetics, CFU, Pseudomonas aeruginosa, Corporation, Bacteria, Treasurer, FDA, CF, Conference, Safety, International, Professional corporation, ECFC, Psoriatic arthritis, Mortality, Research, Therapy, FEV1, Sputum, Workforce, Drug development, Clinical trial, Urinary tract infection, Fast Track, Part, Plasma protein binding, NESS, Phage therapy, Poster, AD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Biogen, Pharmaceutical industry, Medical imaging, Cryptocurrency

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the second quarter ended June 30, 2023.

Key Points: 
  • and NESS ZIONA, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the second quarter ended June 30, 2023.
  • “Our BX004 clinical program in cystic fibrosis (“CF”) continues to build significant momentum,” said Jonathan Solomon, Chief Executive Officer of BiomX.
  • Net loss for the second quarter of 2023 was $6.4 million, compared to $7.5 million for the same period in 2022.
  • BiomX management will host a conference call and webcast today at 8:00 am ET to report financial results and business updates for the second quarter of 2023.

ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics

Retrieved on: 
Monday, June 26, 2023
Food, Therapy, S. aureus, Endocarditis, Escherichia coli, Cosmetics, Research, AMR, Staphylococcus aureus, Death, Patient, Cancer, Phage therapy, Infection, Knee, Chair, Pharmaceutical industry, Vaccine

Lyon (France) and Cambridge (MA, US), June 26, 2023 – ERYTECH (Nasdaq & Euronext: ERYP) and PHERECYDES announce merger and name change to PHAXIAM Therapeutics, a clinical-stage biopharmaceutical company developing innovative extended bacteriophage therapies to target antimicrobial resistance (AMR).

Key Points: 
  • Lyon (France) and Cambridge (MA, US), June 26, 2023 – ERYTECH (Nasdaq & Euronext: ERYP) and PHERECYDES announce merger and name change to PHAXIAM Therapeutics, a clinical-stage biopharmaceutical company developing innovative extended bacteriophage therapies to target antimicrobial resistance (AMR).
  • “In February this year, we announced our strategic plans with PHERECYDES, with the intent to build a global leader in phage therapy and address the huge medical need caused by antimicrobial resistance.
  • I am very pleased that this merger has now been approved with a large majority by our shareholders”, said Gil Beyen, former Chief Executive Officer of ERYTECH.
  • The board of directors of PHAXIAM is composed of an equal number of directors from the former ERYTECH and PHERECYDES boards (without casting vote for the Chair), and is constituted of:

ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023

Retrieved on: 
Friday, June 23, 2023
Shareholder, Bank statement, ADS, Public, Policy, Element, Delegation, Mergers and acquisitions, ISIN, Phage therapy, Combined, Therapy, Security (finance), Holding company, Pherecydes, Euronext Paris, Euronext

The merger between Erytech and Pherecydes has been approved by the Combined General Meeting on the basis of an exchange ratio of 4 Pherecydes shares for 15 Erytech shares (the "Merger") which gave full powers to Erytech's Board of Directors to record the definitive completion of the Merger.

Key Points: 
  • The merger between Erytech and Pherecydes has been approved by the Combined General Meeting on the basis of an exchange ratio of 4 Pherecydes shares for 15 Erytech shares (the "Merger") which gave full powers to Erytech's Board of Directors to record the definitive completion of the Merger.
  • Erytech shareholders also approved the change of Erytech's corporate name to "Phaxiam Therapeutics".
  • At the Pherecydes Combined General Meeting held today at 1pm, after the Erytech Combined General Meeting, all the resolutions supported by the Pherecydes Board of Directors were approved, including those relating to the Merger.
  • The Erytech Board of Directors met after the Pherecydes Combined General Meeting and acknowledged the completion of the Merger.

ERYTECH Responds to Akkadian’s Disinformation

Retrieved on: 
Monday, June 12, 2023
Exercise, Pancreatic cancer, Compagnie Nationale du Rhône, Uncertainty, Communication, Commercial Court, Employment, Annual general meeting, Drug development, Interview, Assembly, ALL, Chapter 11, Title 11, United States Code, Partner, Annual, Abergel, Commissaire, Sale, LOI, Proposed merger of Publicis and Omnicom, Documentation, Acquisition, Risk, CEST, Seriousness, Phage therapy, Knowledge, Infection, AMF, Fraud, Catalent, General assembly, Risk management, Management, Pharmaceutical industry, Cryptocurrency, Pherecydes, Court

Cambridge, MA (U.S.) and Lyon (France), June 12, 2023, 7:00 am CEST – ERYTECH Pharma (Nasdaq & Euronext: ERYP), today reacts to a series of disinformation attempts by Akkadian Partners to try and destabilize ERYTECH.

Key Points: 
  • Cambridge, MA (U.S.) and Lyon (France), June 12, 2023, 7:00 am CEST – ERYTECH Pharma (Nasdaq & Euronext: ERYP), today reacts to a series of disinformation attempts by Akkadian Partners to try and destabilize ERYTECH.
  • The proposed transaction is structured as a merger of PHERECYDES into ERYTECH, pursuant to which PHERECYDES shareholders will receive 15 new ERYTECH shares for every 4 PHERECYDES shares they own.
  • On 13 April, Akkadian Partners, an entity domiciled in Luxembourg, crossed the threshold of 5% of the share capital of ERYTECH Pharma.
  • Finally, it is important to note that a failure of the merger would only lead to the destruction of value for ERYTECH and its shareholders.

Adaptive Phage Therapeutics Enters Collaboration and License Agreement with Hebrew University of Jerusalem and Hadassah Medical Center

Retrieved on: 
Wednesday, May 24, 2023
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Partnership, Al-Quds, Hebrew University of Jerusalem, Technology transfer, Quinone, Nidaa Khoury, Bacteriophage, Infection, Phage therapy, Multimedia, Staphylococcus, Doctor of Philosophy, Staphylococcus aureus, Acinetobacter baumannii, Pseudomonas aeruginosa, Hospital, Rimon School of Jazz and Contemporary Music, IPTC, Biomedicine, Patient, PubMed, Hadassah Medical Center, APT, Bacteria, European Society of Clinical Microbiology and Infectious Diseases, Medicine, Pharmaceutical industry, MD

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, is pleased to announce a collaboration and license agreement with the Israeli Phage Therapy Center (IPTC) of the Hebrew University of Jerusalem and Hadassah Medical Center.

Key Points: 
  • Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, is pleased to announce a collaboration and license agreement with the Israeli Phage Therapy Center (IPTC) of the Hebrew University of Jerusalem and Hadassah Medical Center.
  • APT also has the first right to evaluate additional phages discovered by IPTC researchers for inclusion in APT’s phage bank.
  • “We are thrilled to enter into this collaboration and license agreement and to continue our work with Dr. Nir-Paz, Dr. Hazan, and the impressive group of phage scientists at Hebrew University and Hadassah Medical Center.
  • I am thrilled to see the Israeli Phage Therapy Center entering into a collaboration and licensing agreement with Adaptive Phage Therapeutics, the leading phage therapy biotech firm,” said Ran Nir-Paz, MD, Professor of Clinical Microbiology and Medicine at the department of Clinical Microbiology and Infectious Diseases at the Hadassah Hebrew University Medical Center and co-founder of the Israeli Phage Therapy Center.

ERYTECH Provides Business and Financial Update for the First Quarter of 2023

Retrieved on: 
Tuesday, May 9, 2023
Uncertainty, Pherecydes, Partner, Infection, AMR, President's Management Advisory Board, Acquisition, Management, Phage therapy, General assembly, Fine chemical, Pharmaceutical industry, Security (finance), Cryptocurrency, Clothing

Lyon (France) and Cambridge (MA, US), May 9, 2023 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update for the first quarter of 2023.

Key Points: 
  • Lyon (France) and Cambridge (MA, US), May 9, 2023 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update for the first quarter of 2023.
  • This transaction is the result of the extensive strategic review process announced by ERYTECH on several occasions since November 2021.
  • Note that ERYTECH is not aware of any further acquisitions of ERYTECH shares completed by Akkadian.
  • As of March 31, 2023, ERYTECH had cash and cash equivalents totaling €30.5 million (approximately $33.7 million), compared with €38.8 million as of December 31, 2022.

ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022

Retrieved on: 
Wednesday, March 22, 2023
Pancreatic cancer, ALL, Pherecydes, EGM, Infection, Sale, Seminal vesicles, Patient, Phage therapy, Catalent, FDA, BLA, Pharmaceutical industry, TNBC

Cambridge, MA (U.S.) and Lyon (France), March 22, 2023 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update for the fourth quarter and full year of 2022.

Key Points: 
  • Cambridge, MA (U.S.) and Lyon (France), March 22, 2023 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update for the fourth quarter and full year of 2022.
  • We sold our US manufacturing site, sharply reduced our cash burn, focused on our most promising preclinical programs, and relentlessly pursued partnering options”, said Gil Beyen, Chief Executive Officer of ERYTECH.
  • Linked to the halt of the Company’s lead program Graspa®, a restructuring program was initiated in May 2022.
  • Key financial figures for the twelve months of 2022 compared with the same period of the previous year are summarized below:

BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, August 10, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, U.S. Securities and Exchange Commission, Phage therapy, Saima, SEC, Clinical trial, Security (finance), Research, Bioinformatics, Cystic Fibrosis Foundation, Valencia CF Foundation, Patient, CF, International, KOL, CFF, Part, IBD, Infection, Pseudomonas aeruginosa, Acne, Conditional sentence, Partnership, Safety, Weizmann Institute of Science, Primary sclerosing cholangitis, Internet, Pharmacokinetics, Â, Mortality, Forward-looking statement, Therapy, Boehringer Ingelheim, Program, AD, Investor, Israel Innovation Authority, Organization, Biomarker, Inflammatory bowel disease, Cell, Quantification, NYSE, Psoriatic arthritis, Workforce, Company, Urinary tract infection, Cystic fibrosis, Treatment, Disease, Atopic dermatitis, Private Securities Litigation Reform Act, Colorectal cancer, Pharmaceutical industry, Risk management, Cryptocurrency

BiomX Inc. (NYSE American: PHGE) (BiomX or the Company), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results, and provided a business update for the second quarter ended June 30, 2022.

Key Points: 
  • BiomX Inc. (NYSE American: PHGE) (BiomX or the Company), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results, and provided a business update for the second quarter ended June 30, 2022.
  • Also in June, BiomX announced a second partnership with Boehringer Ingelheim to discover inflammatory bowel disease (IBD) microbiome markers.
  • Net loss for the second quarter of 2022 was $7.5 million, compared to $7.3 million for the same period in 2021.
  • BiomX management will host a conference call and webcast today at 8:00 am ET to report financial results and business updates for the second quarter 2022.

Felix Biotechnology Awarded Competitive Grant from the National Institutes of Health to Power Phage Engineering Platform

Retrieved on: 
Thursday, July 14, 2022
Technology, Global health, Infection, Microfluidics, Lawrence Berkeley National Laboratory, Small Business Innovation Research, Acquisition, Incidence, Multimedia, Yale University, Solution, Engineering, National Science Foundation, Phage therapy, NIH, Bacteria, SBIR, Biotechnology, Machine learning, National Institute, Y Combinator, UCSF, Foundation for the National Institutes of Health, Antibiotics, Pharmaceutical industry, Vaccine

SOUTH SAN FRANCISCO, Calif., July 14, 2022 /PRNewswire/ -- Felix Biotechnology has been awarded a Small Business Innovation Research (SBIR) Phase I grant for $314,411 from the National Institute of Health (NIH) to develop a microfluidics platform for rapid, high-throughput screening of therapeutic bacteriophages that target disease-causing bacteria.

Key Points: 
  • A microfluidics phage screening platform will accelerate the development of generalizable phage therapies targeting deadly antimicrobial resistant bacterial infections.
  • Felix awarded competitive NIH grant to build a microfluidics platform which will accelerate generalizable phage therapy.
  • To reach the clinic, Felix is engineering phage to kill a broader range of bacteria, and this requires large amounts of data on phage-bacteria interactions.
  • Supported by this SBIR grant, Felix will develop new tools that accelerate the acquisition of this critical phage-bacteria interaction data.